Press Release

<< Back
View printer-friendly version

Spark Therapeutics to Host Conference Call on Tuesday, Nov. 7 at 8:30 a.m. ET to Discuss Third Quarter 2017 Results

PHILADELPHIA, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Nov. 7, 2017, at 8:30 a.m. ET to discuss corporate and financial results for the third quarter that ended Sept. 30, 2017 and recent business highlights.

The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 5468349. To access a live audio webcast, please visit the “Investors” section at www.sparktx.com.

A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 5468349, or by visiting the “Investors” section at www.sparktx.com.

About Spark Therapeutics
At Spark Therapeutics, a fully integrated company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia and neurodegenerative diseases. We have successfully applied our technology directed to the retina and liver, and currently have four programs in clinical trials or under regulatory review, including the first potential gene therapy for a genetic disease in the United States and product candidates that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where no life is limited by genetic disease. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn.

Investor Contact:
Ryan Asay
Ryan.asay@sparktx.com
(215) 239-6424

Media Contact:
Monique da Silva
Monique.dasilva@sparktx.com
(215) 282-7470

Source: Spark Therapeutics, Inc.